In the search for new drug targets, that may help point the way to develop fast-acting
treatments for mood disorders, we have explored molecular pathways regulated by …

Major depressive disorder (MDD) is a debilitating disease characterized by depressed
mood, loss of interest or pleasure, suicidal ideation, and reduced motivation or …

Background & Objective: Ketamine, a noncompetitive NMDA receptor antagonist, exhibits
rapid antidepressant actions, but the underlying mechanism remains obscure. AMPA …

Glycogen synthase kinase 3β (GSK3β), originally described as a negative regulator of
glycogen synthesis, is a molecular hub linking numerous signaling pathways in a cell …

Recent clinical studies have demonstrated that a single subpsychotomimetic dose of
ketamine, an ionotropic glutamatergic N-methyl-d-aspartate (NMDA) receptor antagonist …

This study tested if sodium valproate or lithium, two agents used to treat bipolar mood
disorder, altered the regulatory phosphorylations of Akt or glycogen synthase kinase-3β …

Ketamine is an open channel blocker of ionotropic glutamatergic N-Methyl-D-Aspartate
(NMDA) receptors. The discovery of its rapid antidepressant effects in patients with …

Background Glycogen synthase kinase-3 β (GSK3β) is an intracellular enzyme directly
implicated in several neural processes relevant to bipolar disorder (BD) pathophysiology …

Bipolar disorder (BD) is a unique disorder where the same patient exhibits depression and
mania, states with polar opposite mood symptoms. Lithium is an alkali metal that is widely …

The weeks/months it takes for traditional antidepressants to act pose an obstacle in the
management of depression. Ketamine's prompt and sustained antidepressant effects …